Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 18.09.2026 | Accepted 19.09.2026 | Online 23.09.2026

IMMUNOPHARMACOLOGICAL STRATEGIES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

Lukas F. Schneider
Department of Immunopharmacology
Heidelberg Institute for Biomedical Research, Germany
lukas.schneider@hibr-med.de

Abstract.

Autoimmune and chronic inflammatory diseases arise from sustained dysregulation of innate and adaptive immune pathways, loss of self-tolerance, and persistent cytokine-mediated tissue injury. Modern immunopharmacology has shifted treatment from broad immunosuppression toward mechanism-based modulation of selected immune pathways. This structured review evaluates established and emerging pharmacological strategies used in rheumatoid arthritis, inflammatory bowel disease, psoriasis, systemic lupus erythematosus, vasculitis, multiple sclerosis and related immune-mediated disorders. A literature synthesis was performed using contemporary international reviews and translational studies focusing on cytokine blockade, Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibition, B-cell and T-cell directed therapy, complement inhibition, regulatory T-cell manipulation, antigen-specific tolerance, immunoengineering and chimeric antigen receptor (CAR) T-cell approaches. The evidence indicates that TNF, IL-6, IL-17/IL-23 and JAK-STAT targeting can produce rapid and clinically meaningful control of inflammation in selected diseases, while B-cell and complement-directed therapies provide particular benefit when humoral immunity or complement activation is central to pathogenesis. Newer strategies aim not merely to suppress inflammation but to restore durable immune tolerance. The principal limitations remain infection risk, heterogeneous treatment response, high cost, secondary loss of efficacy and incomplete biomarkers for patient selection. Future immunopharmacology is therefore expected to integrate molecular phenotyping, tissue-level biomarkers and adaptive treatment algorithms to achieve more precise and safer immune modulation.

Keywords: immunopharmacology; autoimmune disease; inflammation; biologics; JAK inhibitors; cytokines; regulatory T cells; complement; precision medicine.

1. INTRODUCTION

Autoimmune and immune-mediated inflammatory diseases comprise a heterogeneous group of disorders in which dysregulated immune recognition, abnormal effector-cell activation and failure of regulatory mechanisms lead to chronic tissue injury. Although individual diseases differ in target organs and dominant immune pathways, many share recurring pathogenic modules: overproduction of inflammatory cytokines, persistent activation of antigen-presenting cells, autoreactive B- and T-cell responses, pathogenic autoantibodies, complement activation and defects in regulatory T-cell function. These

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

shared mechanisms provide a rational basis for immunopharmacological targeting and explain why the same drug class can be effective across several apparently unrelated diseases (1,5,8).

Traditional therapy relied heavily on glucocorticoids and broad conventional immunosuppressants. These agents remain important, particularly for induction therapy and severe organ-threatening disease, but their actions are relatively non-selective and long-term exposure is associated with infection, metabolic toxicity, osteoporosis, cytopenias and organ-specific adverse effects. The development of monoclonal antibodies, receptor fusion proteins and targeted small molecules has enabled selective interruption of cytokines, cell-surface molecules and intracellular signalling pathways. Anti-TNF therapy established the feasibility of this paradigm, and the therapeutic landscape has subsequently expanded to IL-6, IL-17, IL-23, BAFF, CD20, JAK, TYK2, complement and multiple co-stimulatory pathways (2,3,4,13,14).

However, precision in target selection does not automatically guarantee precision in clinical outcome. Patients with the same diagnostic label can have markedly different immune signatures, comorbidities, pharmacokinetic behaviour and infection risk. In addition, immune pathways are redundant and adaptive; blockade of one mediator may be bypassed by another pathway or may alter host defence. Contemporary immunopharmacology therefore seeks to combine mechanism-based therapy with biomarker-guided patient selection, dynamic safety monitoring and therapeutic sequencing. Emerging modalities such as CAR T-cell therapy, engineered regulatory T cells and antigen-specific tolerance strategies aim to re-establish immune homeostasis rather than maintain indefinite generalized suppression (1,6,7,11,12).

The objective of this article is to synthesize current immunopharmacological strategies for autoimmune and inflammatory diseases, compare their molecular targets, therapeutic roles and major limitations, and outline future approaches for durable and individualized immune control.

2. MATERIALS AND METHODS

This article was designed as a structured, evidence-based literature review using an IMRAD framework. International peer-reviewed literature published primarily between 2023 and 2025 was prioritized, with emphasis on high-impact reviews covering rheumatology, immunology, drug discovery and translational therapeutics. The synthesis focused on pharmacological strategies with either established clinical use or strong translational relevance in autoimmune and chronic inflammatory diseases.

Sources were selected to represent six mechanistic domains: (1) extracellular cytokine and cytokine-receptor blockade; (2) intracellular kinase inhibition, particularly JAK and TYK2; (3) B-cell and T-cell directed therapy; (4) complement pathway inhibition; (5) regulatory T-cell and tolerance-restoring approaches; and (6) engineered cellular and antigen-specific therapies. For each domain, information was extracted on pharmacological mechanism, representative agents or platforms, disease contexts, therapeutic advantages, clinically relevant safety concerns and major future research needs. Because the aim was

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

comparative mechanistic synthesis rather than meta-analysis, no pooled effect estimate was calculated and no patient-level data were generated.

3. RESULTS

3.1. Cytokine and cytokine-receptor blockade

Cytokine neutralization remains one of the most validated approaches in immunopharmacology. TNF inhibition demonstrated that selective blockade of a dominant inflammatory mediator can modify disease activity in rheumatoid arthritis, inflammatory bowel disease, psoriasis and related disorders. Subsequent biologics targeting IL-6 or its receptor, IL-17, IL-12/23 and IL-23 confirmed that inflammatory networks can be therapeutically interrupted at multiple nodes. The therapeutic value of each target depends on disease-specific biology: IL-23/IL-17 signalling is highly relevant to psoriasis and spondyloarthritis, while IL-6 signalling is particularly important in rheumatoid arthritis and several systemic inflammatory states. In inflammatory bowel disease, the clinical success of TNF and IL-12/23 or IL-23 blockade has reinforced the central role of cytokine networks, although resistance and secondary loss of response remain important problems (3,8,13).

Table 1. Major immunopharmacological strategies in autoimmune and inflammatory diseases

Target / pathway	Drug strategy	Representative applications	Key advantage	Major limitation
TNF	Monoclonal antibodies / receptor fusion	RA, IBD, psoriasis, spondyloarthritis	Strong clinical validation and rapid anti-inflammatory effect	Serious infection risk; non-response or secondary loss of efficacy
IL-6 / IL-6R	Cytokine or receptor blockade	RA, giant-cell arteritis, systemic inflammatory disease	Potent control of systemic inflammation	Infection, neutropenia, liver/lipid abnormalities
IL-17 / IL-23	Selective cytokine blockade	Psoriasis, psoriatic arthritis, axial spondyloarthritis, IBD (IL-23)	High pathway specificity in selected phenotypes	Pathway efficacy differs by disease; infection and mucocutaneous effects

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

Target / pathway	Drug strategy	Representative applications	Key advantage	Major limitation
JAK / TYK2	Oral small-molecule kinase inhibitors	RA, psoriatic disease, IBD, dermatitis and emerging SLE uses	Oral dosing and simultaneous modulation of multiple cytokines	Class-specific safety surveillance; drug interactions and patient selection
B cells / BAFF	CD20 depletion, BAFF inhibition	SLE, vasculitis, selected neurologic autoimmunity	Direct effect on pathogenic humoral immunity	Hypogammaglobulinaemia, infection, variable depth of depletion
Complement	C5/C5a/C5aR or proximal pathway inhibition	ANCA vasculitis and other complement-driven diseases	Mechanistically precise when complement is a disease driver	High cost, infection risk and pathway-specific patient selection
Treg / tolerance	Low-dose cytokine engineering, adoptive Treg, antigen-specific approaches	Experimental and early clinical autoimmune applications	Potential restoration of tolerance rather than chronic suppression	Manufacturing complexity, durability and biomarker uncertainty
CAR-T / deep B-cell reset	Engineered cellular therapy	Severe refractory B-cell mediated autoimmune diseases	Potential profound immune reset and sustained drug-free remission	Cytokine release syndrome, infection, specialized infrastructure and cost

3.2. JAK-STAT and TYK2 pathway inhibition

Intracellular kinase inhibition extends pharmacological control beyond a single extracellular cytokine. JAK inhibitors interfere with signalling downstream of multiple type I and II cytokine receptors and have become established treatments for several immune-mediated disorders. Their oral administration, rapid onset and broad cytokine modulation are major advantages. Nevertheless, the breadth of pathway suppression can

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

also produce safety liabilities. Clinical risk assessment is especially important in older patients, smokers and individuals with cardiovascular, thrombotic, malignant or infectious risk factors. Current evidence supports careful patient selection rather than viewing the class as uniformly high-risk or uniformly interchangeable (2,14). TYK2 has emerged as a more selective target because it participates in type I interferon, IL-12 and IL-23 signalling. Selective TYK2 inhibition is clinically validated in psoriasis and is being evaluated in additional rheumatic diseases, offering the possibility of pathway selectivity distinct from JAK1/2/3 inhibition (4).




Figure 1. Conceptual pathway linking immune dysregulation, pharmacological targets and therapeutic response.

3.3. B-cell, T-cell and complement-directed pharmacology

B-cell directed therapy is particularly relevant when autoantibody formation, antigen presentation and B-cell cytokine production contribute to disease. CD20-directed depletion can provide substantial benefit in antibody-mediated vasculitis and several neurologic or systemic autoimmune conditions, whereas BAFF inhibition targets B-cell survival and has established roles in systemic lupus erythematosus. The broader principle is that cellular targeting may modify several pathogenic functions simultaneously, but the depth and duration of depletion influence infection risk, vaccine responses and immunoglobulin concentrations.

T-cell biology is more complex because effector responses must be reduced without eliminating protective immunity or regulatory control. Pharmacological strategies include co-stimulatory modulation, cytokine pathway inhibition and emerging efforts to expand or engineer regulatory T cells. FOXP3-positive regulatory T cells are central to maintenance

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

of self-tolerance, and defects in their number, stability or function are implicated across autoimmune disease. Therapeutic concepts therefore include low-dose or engineered IL-2 signals, ex vivo expanded Treg products and CAR-Treg approaches designed for tissue- or antigen-specific suppression (5,11).

Complement inhibition is increasingly important in disorders in which complement activation directly amplifies vascular, renal or tissue injury. The success of C5a receptor pathway inhibition in ANCA-associated vasculitis illustrates how mechanistic biomarkers can identify diseases suitable for targeted complement pharmacology. Because complement has essential host-defence functions, especially against encapsulated bacteria, treatment requires vaccination, infection-risk mitigation and careful assessment of which complement node should be inhibited (9,15).

3.4. Emerging tolerance-restoring and cellular strategies

The most ambitious therapeutic goal is durable immune tolerance rather than indefinite suppression. Antigen-specific immunotherapies aim to delete, anergize or regulate autoreactive lymphocytes while preserving protective responses to unrelated antigens. This principle could theoretically reduce infection and malignancy risks associated with generalized immunosuppression, but clinical translation is challenging because relevant autoantigens may be heterogeneous, evolve over time or differ among patients (12). Immunoengineering approaches seek to improve spatial and cellular precision using engineered cytokines, nanoparticles, synthetic receptors and tissue-targeted delivery systems (6,8).

CAR T-cell therapy has produced particular interest in severe refractory autoimmune disease. Deep depletion of CD19-positive B-cell lineages can produce an “immune reset” in selected B-cell-mediated disorders, and early clinical experiences have reported sustained remissions in some highly refractory patients. However, the approach remains intensive and carries risks including cytokine release syndrome, prolonged cytopenias, infection and treatment-related resource burden. CAR T-cell therapy should therefore be viewed as an emerging high-intensity option rather than a routine replacement for established pharmacotherapy (1,7).


Table 2. Comparative positioning of established and emerging immunopharmacological approaches

Approach	Current role	Potential future value	Main monitoring priority
Biologic cytokine blockade	Established standard in multiple diseases	Better biomarker-based target selection and rational combinations	Infection, immunogenicity, organ-specific adverse effects

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

Approach	Current role	Potential future value	Main monitoring priority
JAK/TYK2 inhibition	Established or expanding oral targeted therapy	More selective kinase profiles and individualized risk stratification	Infection, laboratory abnormalities, cardiovascular/thrombotic risk in susceptible patients
B-cell / complement targeting	Established in selected antibody- or complement-driven disease	Earlier mechanistic use in biomarker-defined subgroups	Immunoglobulins, vaccination status, serious infection
Treg / antigen-specific tolerance	Early clinical / translational	Long-term restoration of self-tolerance with less generalized immunosuppression	Durability, immune deviation, manufacturing consistency
CAR-T / engineered cell therapy	Investigational for severe refractory autoimmunity	Drug-free remission after immune reset in selected patients	Cytokine release syndrome, cytopenias, infection and long-term immune reconstitution

Precision immunopharmacology cycle



Treatment is refined iteratively to maximize disease control while minimizing immunosuppression-related harm.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

Figure 2. Precision immunopharmacology as an iterative cycle of phenotyping, target selection, treatment and monitoring.

4. DISCUSSION

The major finding of this synthesis is that successful immunopharmacology increasingly depends on matching a dominant disease mechanism to the narrowest effective intervention. Cytokine blockade is highly effective when a disease is driven by a relatively identifiable inflammatory axis, while kinase inhibitors offer broader intracellular control when multiple cytokines contribute simultaneously. Cellular and complement-directed strategies become especially rational when humoral immunity, autoantibody-producing lineages or complement amplification are central to tissue injury. This mechanistic diversification has transformed treatment options, but it has also made therapeutic sequencing more complex (2,3,4,9,13).

A second important principle is that greater molecular selectivity does not remove the need for clinical risk stratification. TNF, IL-6, JAK, B-cell and complement pathways all contribute to host defence. Their inhibition can therefore increase susceptibility to infection in pathway-specific ways. Small-molecule kinase inhibitors additionally require attention to patient age, cardiovascular and thrombotic risk, interacting drugs and laboratory monitoring. Biologics may generate immunogenicity or lose efficacy over time, whereas profound B-cell depletion can impair humoral immunity. Safety management should consequently be considered part of pharmacodynamic optimization rather than an administrative step after drug selection.

Third, response heterogeneity remains a central limitation. Diagnostic categories do not always correspond to a single molecular pathway, and two patients with the same disease may respond differently to the same target. Current treatment algorithms still rely heavily on trial-and-error sequencing. Future practice is likely to incorporate transcriptomic, proteomic, cellular and tissue-level biomarkers together with conventional clinical phenotyping. The aim is to identify the active inflammatory circuit before therapy, verify pathway suppression after treatment, and switch mechanisms when residual inflammation is driven by a different network. Immunoengineering and targeted delivery could further reduce systemic exposure while preserving local efficacy (6).

The emergence of tolerance-restoring approaches represents a conceptual shift from chronic immune suppression toward immune re-education. Treg-directed therapy, antigen-specific tolerance and CAR-based cellular platforms may eventually provide prolonged remission after finite treatment. However, these approaches remain constrained by manufacturing complexity, cost, uncertain durability and the need for rigorous long-term safety surveillance. CAR T-cell therapy is particularly promising for highly selected refractory B-cell-driven disease but should currently be interpreted within the context of early clinical experience rather than routine population-level therapy (7,11,12).

This review has limitations. It is a structured narrative synthesis rather than a formal systematic review or meta-analysis, and the rapid pace of drug development means that regulatory status and evidence maturity can change quickly. Nevertheless, the included

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 18.09.2026 | Accepted 19.09.2026 | Online 23.09.2026

sources capture the major contemporary mechanisms that define current immunopharmacological practice and the directions most likely to influence future treatment design.

5. CONCLUSION

Immunopharmacology has progressed from non-selective immunosuppression to mechanism-based control of cytokines, intracellular kinases, B cells, T cells and complement. Established biologics and targeted small molecules can achieve substantial disease control when pathway selection is aligned with disease biology, but infection risk, loss of response, comorbidity-related toxicity and treatment heterogeneity remain important limitations. The next phase of therapeutic development is likely to combine immune profiling with selective pharmacology, engineered delivery and tolerance-restoring cellular or antigen-specific strategies. The long-term goal is not simply stronger immunosuppression, but individualized intervention capable of controlling pathogenic immunity while preserving protective immune function and, where possible, restoring durable self-tolerance.

REFERENCES

1. Ramirez-Valle, F., Maranville, J. C., Roy, S., et al. (2024). Sequential immunotherapy: towards cures for autoimmunity. Nature Reviews Drug Discovery, 23, 501-524.
2. Szekanecz, Z., Buch, M. H., Charles-Schoeman, C., et al. (2024). Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nature Reviews Rheumatology, 20, 101-115.
3. Neurath, M. F. (2024). Strategies for targeting cytokines in inflammatory bowel disease. Nature Reviews Immunology, 24, 559-576.
4. Morand, E., Merola, J. F., Tanaka, Y., Gladman, D., & Fleischmann, R. (2024). TYK2: an emerging therapeutic target in rheumatic disease. Nature Reviews Rheumatology, 20, 232-240.
5. Sumida, T. S., Cheru, N. T., & Hafler, D. A. (2024). The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases. Nature Reviews Immunology, 24, 503-517.
6. McBride, D. A., Jones, R. M., Bottini, N., & Shah, N. J. (2024). The therapeutic potential of immunoengineering for systemic autoimmunity. Nature Reviews Rheumatology, 20, 203-215.
7. Mougiakakos, D., et al. (2024). Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nature Reviews Rheumatology, 20, 531-544.
8. Leonard, W. J., & Lin, J.-X. (2023). Strategies to therapeutically modulate cytokine action. Nature Reviews Drug Discovery, 22, 827-854.
9. Mastellos, D. C., Hajishengallis, G., & Lambris, J. D. (2024). A guide to complement biology, pathology and therapeutic opportunity. Nature Reviews Immunology, 24, 118-141.

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 18.09.2026 | Accepted 19.09.2026 | Online 23.09.2026

10. Becher, B., Derfuss, T., & Liblau, R. (2024). Targeting cytokine networks in neuroinflammatory diseases. Nature Reviews Drug Discovery, 23, 862-879.
11. Wardell, C. M., Boardman, D. A., & Levings, M. K. (2025). Harnessing the biology of regulatory T cells to treat disease. Nature Reviews Drug Discovery, 24, 93-111.
12. Buckner, J. H. (2025). Antigen-specific immunotherapies for autoimmune disease. Nature Reviews Rheumatology, 21, 88-97.
13. Croft, M., Salek-Ardakani, S., & Ware, C. F. (2024). Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nature Reviews Drug Discovery, 23, 939-961.
14. Castelo-Soccio, L., Kim, H., Gadina, M., Schwartzberg, P. L., Laurence, A., & O'Shea, J. J. (2023). Protein kinases: drug targets for immunological disorders. Nature Reviews Immunology, 23, 787-806.
15. Holers, V. M. (2023). Complement therapeutics are coming of age in rheumatology. Nature Reviews Rheumatology, 19, 470-485.